Skip to main content
OpenTrials
Completed

NCT Number: NCT00922272

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as measured by the Scale for the Assessment of Negative Symptoms (SANS).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

K&S Professional Research Services, Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-55
  • Clinically stable Schizophrenia and predominant negative symptoms
  • Taking a stable dose of antipsychotic medication

Exclusion criteria

  • Clinically notable positive symptoms defined by PANSS

Treatment and study plan

SPD489 (Lisdexamfetamine dimesylate)

Drug

oral, 20, 30, 40, 50, 60, or 70 mg once daily

Other names: Vyvanse

Placebo matching SPD489 (lisdexamfetamine dimesylate)

Drug

oral, once daily

Primary outcomes

  1. Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF)

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

  2. Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF)

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Secondary outcomes

  1. Percent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase

    Time frame: Week 10 Open-label Phase

    Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

  2. Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase

    Time frame: Week 4 Double-blind Phase

    Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

  3. Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

  4. Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

    The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

  5. Change From Open-label Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at Week 10 Open-label Phase, LOCF

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

  6. Change From Double-blind Randomization Baseline in PANSS Scores at Week 4 Double-blind Phase, TOCF

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

  7. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Open-label Baseline

    Time frame: Open-label Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

  8. Percent of Participants With CGI-S at Week 10 Open-label Phase

    Time frame: Week 10 Open-label Phase

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

  9. Percent of Participants With CGI-S at Double-blind Randomization Baseline

    Time frame: Double-blind Randomization Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

  10. Percent of Participants With CGI-S at Week 4 Double-blind Phase

    Time frame: Week 4 Double-blind Phase

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

  11. Percent of Participants With Improvement on Clinical Global Impression - Change (CGI-C) at Week 10 Open-label Phase

    Time frame: Open-label Phase Week 10

    CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

  12. Percent of Participants With Improvement on CGI-C at Week 4 Double-blind Phase

    Time frame: Double-blind Phase Week 4

    CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

  13. Change From Open-label Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Total Score at Week 10 Open-label Phase

    Time frame: Open-label Baseline and week 10 Open-label Phase

    BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.

  14. Change From Double-blind Randomization Baseline in BACS Total Score at Week 4 Double-blind Phase

    Time frame: Double-blind Randomization Baseline and Week 4

    BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.

  15. Change From Open-label Baseline in Letter-Number Span Test (LNS) Total Score at Week 10 Open-label Phase

    Time frame: Open-label Baseline and week 10 Open-label Phase

    LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.

  16. Change From Double-blind Randomization Baseline in LNS Total Score at Week 4 Double-blind Phase

    Time frame: Double-blind Randomization Baseline and Week 4

    LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.

  17. Change From Open-label Baseline in Hopkins Verbal Learning Test - Revised (HVLT-R) Total Score at Week 10 Open-label Phase

    Time frame: Open-label Baseline and Week 10

    HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.

  18. Change From Double-blind Randomization Baseline in HVLT-R Total Scores at Week 4 Double-blind Phase

    Time frame: Double-blind Randomization Baseline and week 4 Double-blind Phase

    HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.

  19. Change From Open-label Baseline in University of California Performance-Based Skills Assessment, Brief Version (UPSA-B) Scores at Week 10 Open-label Phase, LOCF

    Time frame: Open-label Baseline and week 10 Open-label Phase

    UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.

  20. Change From Double-blind Randomization Baseline in UPSA-B Scores at Week 4 Double-blind Phase

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

    UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.

  21. Change From Open-label Baseline in Behavioral Rating Inventory of Executive Function - Adult Version (BRIEF-A) T-scores at Week 10 Open-label Phase

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

  22. Change From Double-blind Randomization Baseline in BRIEF-A T-Scores at Week 4 Double-blind Phase

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

    BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

  23. Change From Open-label Baseline in Simpson Angus Scale (SAS) Total Score at Week 10 Open-label Phase

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

  24. Change From Open-label Baseline in SAS Total Score at Week 4 of Double-blind Phase

    Time frame: Open-label Baseline and Week 4 Double-blind Phase

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

  25. Change From Open-label Baseline in Barnes Akathisia Scale (BAS) Scores at Week 10 Open-label Phase

    Time frame: Open-label Baseline and week 10 Open-label Phase

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

  26. Change From Open-label Baseline in BAS Scores at Week 4 of Double-blind Phase

    Time frame: Open-label Baseline and Week 4 Double-blind Phase

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

  27. Change From Open-label Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 10 Open-label Phase

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

  28. Change From Double-blind Randomization Baseline in ACSA Total Score at Week 4 Double-blind Phase

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

  29. Change From Open-label Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Global Score at Week 10 Open-label Phase

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.

  30. Change From Open-label Baseline in PSQI Total Global Score at Week 4 of Double-blind Phase

    Time frame: Open-label Baseline and Week 4 Double-blind Phase

    PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.

  31. Change From Open-label Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at Week 10 Open-label Phase

    Time frame: Open-label Baseline and Week 10 Open-label Phase

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

  32. Change From Open-label Baseline in CDSS at Week 4 of Double-blind Phase

    Time frame: Open-label Baseline and Week 4 of Double-blind Phase

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Sponsors and collaborators

Lead sponsor

Shire

Industry

Registry information

Official study title

A Phase 2, Multicenter Study With Open-label & Randomized Double-blind Placebo-controlled Withdrawal Phases to Evaluate the Efficacy, Safety, & Tolerability of SPD489 in Adults With Schizophrenia & Predominant Negative Symptoms Who Are Clinically Stable & Taking Stable Doses of Atypical Antipsychotic Medication

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Jun 17, 2009
Registry last updated
Jun 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.